Study on the interest of applying anesthetic cream before intramuscular botulinum toxin injections in children and adolescents with cerebral palsy Objective.-To study the interest of the use of an anesthetic cream in prevention of the pain during the injections of botulinum toxin at the child and the teenager.
Method.-The evaluation is realized in two populations of cerebral palsy children and teenagers. A population receives the application of anesthetic cream before the injections. Other population is injected without anesthetic cream. The pain is estimated by a score EVA or a scal of CHEOPS according to the capacities of the patient. The ''reactivity'' is appreciated in ''important, average, low, no''. In 2011, we presented a preliminary study but series, too small did not allow a statistical study.
Results.-We have 193 medical records. The clinical forms were variable (classification GMFCS). Ninety-seven were evaluated their pain on an EVA, 96 other, are estimated by the CHEOPS. Ninety-six had received anesthetic cream, 97 were injected without. Two populations were homogeneous. The average of EVA is 2,9 with the cream 2 without. The average of CHEOPS is 7 with the cream, 7,2 without. We also analyze the results according to the age, to the number of muscles, concerned limbs or an adjuvating treatment.
Discussion.-Other factors such as the waiting time before injection is probably involved in the patient's anxiety. The passage of the skin seems to us also less painful since we use the electric stimulation, the needles being finer. It is more often to the injection of the product than to the passage of the skin that the child reacts.
Conclusion.-This work does not justify the usefulness of applying an anesthetic cream prior to injections of botulinum toxin in cerebral palsy children and adolescents to decrease the pain induced. [1] . Its interest in early management is supported by its effects on neurovegetative crisis [2] . Materials and methods.-A 61-year-old female patient in persistent vegetativenervous state two months after a bilateral anterior cerebral artery stroke, presented with spastic tetraplegia and equine retracted feet despite an optimal antispastic treatment (oral treatment and botulinum toxin injections). Considering a global muscle hypertonia with a mean score (MAS) of 3.8 on inferior limbs and 3 on superior limbs, and after positive intrathecal baclofen test, pump implantation was decided on day 90 after stroke.
Results.-An improvement of hypertonia of 2 points (MAS) on inferior limbs and of 1.4 on superior limbs facilitating the patient's nursing and bed positioning, as well as an improvement of WHIM of 21 points were noted one week after treatment. No complication was reported.
Discussion.-A diffuse muscle hypertonia with secondary neuro-orthopedic complications can appear in early stages after a severe brain damage. Our case emphasizes the importance of screening and early management of those muscle tonus troubles, with particular interest in early intrathecal baclofen treatment.
Complications were due to baclofen side effects in 16%, equipment dysfunction in 29% and postoperative complications in 55%. 63% of NI or R patients had adverse events vs 7% of FI patients.
Discussion.-The incidence of AE in our study was 0,27 complications per pump-year. This was more that Bensmail et al. [1] observed. They described 0,11 complications per pump-year in 44 MS patients in a 12-years follow-up, but only equipment dysfunctions were collected. Tassëel-Ponche et al. [2] reported 72% of AE in a population of 25 cerebral palsy in a 10-years follow-up, with 0,07 serious complications per pump-year (required an hospitalization), vs. 0,014 in our study.
Conclusion.-This prospective study collected AE occurring after ITB pump placement in a large population. Procedures should be created to reduce the incidence of these AE.
